SOURCE: Eli Lilly and CompanyDESCRIPTION:
Today's guest blog comes from Lilly's Vice President of Global Health Programs and Access, Dr. Evan Lee.
The World Health Organization reported some promising news this week: confirmed diagnoses of multidrug-resistant TB (MDR-TB) cases more than tripled between 2009 and 2013 in 27 countries targeted through an innovative collaboration called EXPAND-TB.
Why is this a good thing? Because diagnosis is the critical first step in treating and caring for people affected by MDR-TB. It is also important for their families and friends, who are at risk and other close contacts in the community. Yet most cases are missed – in 2012, less than a quarter of the 450,000 people estimated to have fallen ill with MDR-TB were diagnosed and officially notified to ministries of health.
Through initiatives like EXPAND-TB, we are starting to close that gap.
KEYWORDS: Health, MDR-TB, multidrug-resistant tuberculosis, Lilly, Eli Lilly, Corporate Responsibility, tuberculosis